ArticleClinical and vaccine immunology : CVI2012
Extended safety and efficacy studies of the attenuated Brucella vaccine candidates 16 M(Delta)vjbR and S19(Delta)vjbR in the immunocompromised IRF-1-/- mouse model.
Article in Clinical and vaccine immunology : CVI, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Evaluation of immune responses toFrontiers in veterinary science · 2022Pooled it
- Brucellosis vaccine development: immunological mechanisms, animal models, and future directions.Archives of microbiology · 2026Review
- The atypical quorum sensing system of classicalJournal of bacteriology · 2025Review
- Quorum sensing LuxR proteins VjbR and BabR jointly regulateJournal of bacteriology · 2025Article
- Preparation and application of aFrontiers in immunology · 2024Article
- Engineering live attenuated vaccines: Old dogs learning new tricks.Journal of translational autoimmunity · 2023Review
- Combined immunization with inactivated vaccine reduces the dose of live B. abortus A19 vaccine.BMC veterinary research · 2022Article
- Live attenuated bacterium limits cancer resistance to CAR-T therapy by remodeling the tumor microenvironment.Journal for immunotherapy of cancer · 2022Article
- Mechanism and strategies of immunotherapy resistance in colorectal cancer.Frontiers in immunology · 2022Review
- Intratracheal inoculation results in Brucella-associated reproductive disease in male mouse and guinea pig models of infection.Frontiers in microbiology · 2022Article
- Evaluation of the safety profile of the vaccine candidate Brucella melitensis 16MΔvjbR strain in goats.Vaccine · 2021Article
- Brucella abortus and Pregnancy in Mice: Impact of Chronic Infection on Fertility and the Role of Regulatory T Cells in Tissue Colonization.Infection and immunity · 2020Article
- Intratracheal Inoculation with Brucella melitensis in the Pregnant Guinea Pig Is an Improved Model for Reproductive Pathogenesis and Vaccine Studies.Infection and immunity · 2020Article
- Vaccine Candidate Brucella melitensis 16MmSphere · 2020Article
- The NOD-Infection and immunity · 2019Article
- Immune Response to MucosalFrontiers in immunology · 2019Review
- A Neglected Animal Model for a Neglected Disease: Guinea Pigs and the Search for an Improved Animal Model for Human Brucellosis.Frontiers in microbiology · 2018Review
- Brucella abortus ΔrpoE1 confers protective immunity against wild type challenge in a mouse model of brucellosis.Vaccine · 2016Article
- The Case for Live Attenuated Vaccines against the Neglected Zoonotic Diseases Brucellosis and Bovine Tuberculosis.PLoS neglected tropical diseases · 2016Review
- Pathogenesis and immunobiology of brucellosis: review of Brucella-host interactions.The American journal of pathology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
The global distribution of brucellosis and high incidence in certain areas of the world warrant the development of a safer and efficacious vaccine. For the past 10 years, we have focused our attention on the development of a safer, but still highly protective, live attenuated vaccine for human and animal use. We have demonstrated the safety and protective efficacy of the vaccine candidates 16 MΔvjbR and S19ΔvjbR against homologous and heterologous challenge in multiple immunocompetent animal models, including mice and deer. In the present study, we conducted a series of experiments to determine the safety of the vaccine candidates in interferon regulatory factor-1-knockout (IRF-1(-/-)) mice. IRF-1(-/-) mice infected with either wild-type Brucella melitensis 16 M or the vaccine strain Brucella abortus S19 succumb to the disease within the first 3 weeks of infection, which is characterized by a marked granulomatous and neutrophilic inflammatory response that principally targets the spleen and liver. In contrast, IRF-1(-/-) mice inoculated with either the 16 MΔvjbR or S19ΔvjbR vaccine do not show any clinical or major pathological changes associated with vaccination. Additionally, when 16 MΔvjbR- or S19ΔvjbR-vaccinated mice are challenged with wild-type Brucella melitensis 16M, the degree of colonization in multiple organs, along with associated pathological changes, is significantly reduced. These findings not only demonstrate the safety and protective efficacy of the vjbR mutant in an immunocompromised mouse model but also suggest the participation of lesser-known mechanisms in protective immunity against brucellosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.